Abstract:Abacavir (1592U89, or Ziagen) is a powerful and selective inhibitor of HIV-1 viral replication that has been approved by the FDA for treatment of acquired immunodeficiency syndrome. Abacavir is metabolized to the active compound carbovir triphosphate (CBVTP). This compound is a guanosine analogue containing a 2,3-unsaturation in its planar carbocyclic deoxyribose ring that acts on HIV-1 reverse transcriptase (RTWT) as a molecular target, resulting in chain termination of DNA synthesis. A single amino acid change from methionine 184 to valine in HIV-1 RT (RTM184V) has been observed clinically in response to abacavir treatment. The ability of the natural substrate, dGTP, or CBVTP to be utilized during DNA- and RNA-directed polymerization by RTWT and RTM184V was defined by pre-steady-state kinetic parameters. In the case of RVWT, CBVTP was found to be a surprisingly poor substrate relative to dGTP. In both DNA- and RNA-directed polymerization, a decrease in the efficiency of CBVTP utilization with respect to dGTP was found with RTM184V, suggesting that this mutation confers resistance at the level of CBVMP incorporation. The relatively low incorporation efficiency for RTWT was unanticipated considering earlier studies showing that the triphosphate form of a thymidine nucleoside analogue containing a planar 2',3'-unsaturated ribose ring, D4TTP, was incorporated with high efficiency relative to the natural substrate, dTTP. The difference may be related to the isosteric replacement of oxygen in the deoxyribose ring with carbon. This hypothesis was tested by synthesizing and evaluating D4GTP (the planar 2'X-unsaturated deoxyribose guanosine analogue that is complementary to D4TTP). In contrast to CBVTP, D4GTP was found to be an excellent substrate for RTWT and no resistance was conferred by the M184V mutation, thus providing novel insight into structure-activity relationships for nucleoside-based inhibitors. In this work, we illustrate how an understanding of the molecular mechanism of inhibition and drug resistance led to the discovery of a novel prodrug of D4G. This compound shows promise as a potent antiviral especially with the drug resistant M184V HIV-1 RT that is so often encountered in a clinical setting.

Study on the interaction between HIV reverse transcriptase and its non-nucleoside inhibitor nevirapine by capillary electrophoresis.

Quantum chemical and experimental study of closed-loop reactant of nevirapine

Kinetic study of CYP3A4 activity on verapamil by capillary electrophoresis.

Study On The Interaction Of Human Immunodeficiency Virus Inhibitor, Trans-Activitor Of Transcription Protein And Ribonucleic Acid System By Capillary Electrophoresis

Study on Evaluation of Human Immunodeficiency Virus Reverse Transcriptase Inhibitor by ELISA

Study on the Interactions Between Anti-Hiv-1 Active Compounds with Trans-Activation Response RNA by Affinity Capillary Electrophoresis

Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture

Clinical uses of non-nucleoside reverse transcriptase inhibitors

Assessment of the susceptibility of mutant HIV-1 to antiviral agents.

A Biochemical/Biophysical Assay Dyad for HTS-Compatible Triaging of Inhibitors of the HIV-1 Nef/Hck SH3 Interaction

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

Study on Steady‐state Kinetics of Nucleotide Analogues Incorporation by Non‐gel CE

Determination of serum nevirapine by RP-HPLC

Interactive Study Between Two Types of 1-[2-(hydroxyethoxy)methyl]-6-naphthylmethylthymines and HIV-1 Reverse Transcriptase

Studies of binding constants and interaction of drugs to -activation response RNA by capillary electrophoresis

Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients

Insights into the Molecular Mechanism of Inhibition and Drug Resistance for HIV-1 RT with Carbovir Triphosphate.

Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains

Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells

New strategy for identifying potential natural HIV-1 non-nucleoside reverse transcriptase inhibitors against drug-resistance: an in silico study

Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses